Lipidor appoints new CFO Charlotta Ekman

STOCKHOLM, Sweden, 25 August 2022 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that Charlotta Ekman has been appointed new Chief Financial Officer of Lipidor. In the role of CFO, Charlotta will also be part of Lipidor’s management team. She will take office on 1st October.

Charlotta Ekman has broad experience from senior positions as CFO and COO at development and growth companies such as Minesto AB and Acosense AB. Most recently, she comes from a self-employed consulting role in business and operational development where, among other things, she has had a consulting assignment at Lipidor since November 2021. Charlotta is a trained economist and has a degree from Chalmers School of Entrepreneurship.

In addition to responsibility for Lipidor’s finance functions, there will be an emphasis in the work on strategy implementation, organization and management, in close collaboration with the company’s CEO.

“Charlotta has a solid background and experience with B2B companies in the growth phase of an international market,” says Ola Holmlund, Lipidor CEO. “She will have an important operational and strategic role in the company, given the company’s ambitions and agenda. It makes her a perfect fit for Lipidor and we are very happy to welcome her to us.”

Holmlund adds, “I would also like to take this opportunity to thank our outgoing CFO Michael Owens for his excellent collaboration during these years. Michael has been a great support in complex issues and not least in Lipidor’s IPO.”

Publication

The information was provided for publication by Lipidor’s CEO on 25 August 2022 at 2.30pm CEST.

For more information, please contact:

Ola Holmlund, CEO
Telephone: +46 (0)72 50 70 369
Email: ola.holmlund@lipidor.se

Certified Adviser

Erik Penser Bank AB
Telephone: +46 (0)8 463 80 00
E-mail: certifiedadviser@penser.se

About Lipidor AB

Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.